Oxygen Double Bonded To A Ring Carbon Of The Cyclopentanohydrophenanthrene Ring System Patents (Class 514/177)
  • Patent number: 10802030
    Abstract: Provided are systems and methods to identify subjects at risk for preterm labor and/or preterm birth. The systems and methods utilize biomarkers. Also provided are systems and methods for decreasing the risk of preterm labor by administering a treatment following a positive risk identification.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: October 13, 2020
    Assignees: Wayne State University, The United States of America as Represented by the Secretary, Department of Health and Human Service
    Inventors: Adi L. Tarca, Offer Erez, Tinnakorn Chaiworapongsa, Sonia S. Hassan, Roberto Romero
  • Patent number: 10758548
    Abstract: The present invention relates to methods and pharmaceutical compositions for treating peripheral demyelinating diseases. In particular the present invention relates to a method of treating a peripheral demyelinating disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an inhibitor of VDAC1 activity or expression.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: September 1, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE MONTPELLIER
    Inventors: Nicolas Tricaud, Sergio Gonzalez
  • Patent number: 10736907
    Abstract: A method of stabilizing tibolone in a solid dosage form using a sugar-alcohol, and a pharmaceutical composition, in particular a solid dosage form such as a tablet, including tibolone, a sugar-alcohol and a non-sugar-alcohol diluent. The weight ratio of the sugar-alcohol to the non-sugar-alcohol diluent is between 4:1 and 1:4.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: August 11, 2020
    Assignee: NOVALON S.A.
    Inventor: Séverine Jaspart
  • Patent number: 10716795
    Abstract: Provided are steroid analogues functionalized with polar substituents at the C3 and/or C20 positions of the steroid ring system that exhibit improved water solubility. Also provided are pharmaceutical compositions comprising the steroid analogues and methods using the novel steroid analogues for the treatment and prevention of neurodegeneration in a patient following injury to the central nervous system.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: July 21, 2020
    Assignee: Emory University
    Inventors: Christopher MacNevin, Donald G. Stein, Dennis C. Liotta, Iqbal Sayeed, David B. Guthrie, Mark A. Lockwood, Michael G. Natchus
  • Patent number: 10688122
    Abstract: Described herein are compositions and methods for the increasing the quantity of lipids secreted from meibomian glands. Such compositions and methods are useful for the treatment of meibomian gland dysfunction and disorders resulting therefrom.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: June 23, 2020
    Assignee: AZURA OPHTHALMICS LTD.
    Inventors: Shimon Amselem, Yair Alster, Doron Friedman, Omer Rafaeli
  • Patent number: 10574846
    Abstract: An image scanner includes a document detector configured to, each time line scanning is repeated a predetermined number of times, perform an edge detecting process to detect a position of a lateral side extending in a sub scanning direction from a non-reference corner of a sheet, in the edge detecting process performed for a first time, set a position of the non-reference corner in a main scanning direction as a detection reference position, in the edge detecting process performed for a second or later time, set a previously-detected position of the lateral side in the main scanning direction as the detection reference position, and in each edge detecting process, set a detection range in the main scanning direction on the basis of the detection reference position, and detect a specific pixel corresponding to the lateral side in the main scanning direction within the detection range in the main scanning direction.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: February 25, 2020
    Assignee: BROTHER KOGYO KABUSHIKI KAISHA
    Inventor: Isamu Fujii
  • Patent number: 10561671
    Abstract: The present invention relates to a method of enhancing retention of recognition memory and/or recovering recognition memory deficits using 3?-methoxy-pregna-5-ene-20-one.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: February 18, 2020
    Assignee: MAPREG
    Inventors: Etienne-Emile Baulieu, Esther Fellous, Paul Robel
  • Patent number: 10561615
    Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage forms containing testosterone undecanoate, as well as related methods of treatment. In one embodiment, the oral dosage form can include a therapeutically effective amount of testosterone undecanoate and a pharmaceutically acceptable carrier. The dosage form can be formulated such that, when measured using a USP Type II apparatus in 1000 mL of 8 wt % Triton X-100 in water at 37° C. and 100 rpm, the oral dosage form releases at least 20% more testosterone undecanoate after the first 120 minutes than an equivalent dose testosterone undecanoate containing oral dosage form without the pharmaceutically acceptable carrier.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: February 18, 2020
    Assignee: Lipocine Inc.
    Inventors: Basawaraj Chickmath, Chandrashekar Giliyar, Nachiappan Chidambaram, Mahesh Patel, Srinivasan Venkateshwaran
  • Patent number: 10538550
    Abstract: The invention relates to compounds of formula (I) wherein R1, R2, Y1, R4 and R5 are as defined herein. The compounds are intermediates in the synthesis of synthetic bile acid derivatives with pharmacological activity. The invention further provides methods related to the synthesizing of these intermediates, and methods of preparing obeticholic acid and obeticholic acid analogues from the compounds of the invention.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: January 21, 2020
    Assignee: NZP UK Limited
    Inventors: Alexander Weymouth-Wilson, Zofia Komsta, James Boydell, Laura Wallis, Rhys Batchelor, Carl Otter, Ieuan Davies
  • Patent number: 10532059
    Abstract: This disclosure provides a novel pharmaceutical composition for delivering steroid hormones to a patient in need thereof.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: January 14, 2020
    Assignee: TherapeuticsMD, Inc.
    Inventors: Annette Shadiack, Peter H. R. Persicaner, Philip B. Inskeep, Thorsteinn Thorsteinsson, Frederick D. Sancilio, Jason D. Legassie
  • Patent number: 10471074
    Abstract: This disclosure provides a novel pharmaceutical composition for delivering steroid hormones to a patient in need thereof.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: November 12, 2019
    Assignee: TherapeuticsMD, Inc.
    Inventors: Annette Shadiack, Peter H. R. Persicaner, Philip B. Inskeep, Thorsteinn Thorsteinsson, Frederick D. Sancilio, Jason D. Legassie
  • Patent number: 10413508
    Abstract: An improved process for producing an oil-in-water emulsion to deliver a substantially water insoluble active pharmaceutical ingredient includes creating a microemulsion containing such ingredient in the oil phase of the emulsion by mixing an aqueous phase including non-ionic surfactant, polyol, and water, wherein the weight ratio of the surfactant to polyol to water is between 10:20:70 and 1:1:1, to generate a mixture, with an oil phase comprising a substantially water insoluble active pharmaceutical ingredient and a long-chain triglyceride; circulating the said mixture through a homogenizer at a temperature from 20° C. to 60° C. to generate a coarse emulsion; passing the coarse emulsion through a microfluidizer at a pressure of from 70 MPa to 150 MPa at least once to produce an oil-in-water microemulsion; and, optionally, filtering the microemulsion through a 0.2 ?m filter and/or mixing the microemulsion with a polymeric stabilizer.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: September 17, 2019
    Assignee: R. P. Scherer Technologies, LLC
    Inventors: James Michael Foreman, Anayo Michael Ukeje, Ronald W. Swank, Waiken Wong
  • Patent number: 10322138
    Abstract: Pregn-4-en-20-yn-3?-one is useful in the treatment of depressive disorders by nasal administration.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: June 18, 2019
    Assignee: PHERIN PHARMACEUTICALS, INC.
    Inventor: Louis Monti
  • Patent number: 10295527
    Abstract: A process and system directed to a more effective, individual based treatment regimen which is built on clinical identified target biomarkers associated with gender differential responses to mesalamine, and includes one or more panels of target biomarkers that distinguishes mesalamine response differences between genders and determines the efficacy of mesalamine for patients being treated for various UC conditions and effectively identifies and validates novel drug targets for new UC therapeutics, new diagnostics and diagnostics standards for UC therapeutic strategies.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: May 21, 2019
    Inventors: Bruce Yacyshyn, Mary E. Yacyshyn
  • Patent number: 10253369
    Abstract: Provided are methods of determining whether a subject having ER+ breast cancer is expected to benefit from treatment with combination endocrine therapy and mTOR inhibitor therapy. Also provided are methods of treating a subject having ER+ breast cancer.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: April 9, 2019
    Assignee: BIOTHERANOSTICS, INC.
    Inventors: Catherine Schnabel, Yi Zhang, Mark G. Erlander
  • Patent number: 10213440
    Abstract: Formulations for oral transmucosal compositions including a synergistic combination of low doses of testosterone with an aromatase inhibitor (AI) that are combined with transmucosal absorption enhancers are disclosed. Oral transmucosal compositions can be for fast release or slow release, and can be administered to increase bloodstream testosterone levels and thereby reduce symptoms of testosterone deficiency. Oral transmucosal compositions include liquid dosage forms, solid dosage forms, and chewing gums. Further dosage forms include mucoadhesive thin strips, thin films, tablets, patches, and tapes, among others. Other dosage forms are: mucoadhesive liquids such as gel-forming liquids; gel-forming semisolids; and gel-forming powders, among other dosage forms that exhibit mucoadhesive properties, and provide oral transmucosal delivery of testosterone and AI.
    Type: Grant
    Filed: April 13, 2015
    Date of Patent: February 26, 2019
    Assignee: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA (PCCA)
    Inventors: Tsu-I Catherine Wang, Bruce Vincent Biundo
  • Patent number: 10022384
    Abstract: The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier.
    Type: Grant
    Filed: April 5, 2016
    Date of Patent: July 17, 2018
    Assignee: Lipocine Inc.
    Inventors: Chandrashekar Giliyar, Srinivasan Venkateshwaran, Basawaraj Chickmath, Satish Kumar Nachaegari, Nachiappan Chidambaram, Mahesh V. Patel
  • Patent number: 9968554
    Abstract: Drag derivatives are provided herein which are suitable for loading into liposomal nanoparticle carriers. In some preferred aspects, the derivatives comprise a poorly water-soluble drag derivatized with a weak-base moiety that facilitates active loading of the drag through a LN transmembrane pH or ion gradient into the aqueous interior of the LN. The weak-base moiety can optionally comprise a lipophilic domain that facilitates active loading of the drag to the inner monolayer of the liposomal membrane. Advantageously, LN formulations of the drag derivatives exhibit improved solubility, reduced toxicity, enhanced efficacy, and/or other benefits relative to the corresponding free drags.
    Type: Grant
    Filed: June 12, 2014
    Date of Patent: May 15, 2018
    Assignee: The University of British Columbia
    Inventors: Pieter Cullis, Marcel Bally, Marco Ciufolini, Norbert Maurer, Igor Jigaltsev
  • Patent number: 9949926
    Abstract: The present invention aims to provide an eye drop for treating macular edema. The present invention provides an eye drop for treating macular edema, which contains difluprednate as an active ingredient. The eye drop can afford effects such as improvement of visual acuity and decreased foveal retinal thickness in macular edema.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: April 24, 2018
    Assignee: YAMAGATA UNIVERSITY
    Inventors: Hidetoshi Yamashita, Teiko Yamamoto, Sakiko Goto, Sachi Abe, Eriko Kirii, Atsushi Okumura
  • Patent number: 9931349
    Abstract: This disclosure provides a novel pharmaceutical composition for delivering steroid hormones to a patient in need thereof.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: April 3, 2018
    Assignee: TherapeuticsMD, Inc.
    Inventors: Annette Shadiack, Peter H. R. Persicaner, Philip B. Inskeep, Thorsteinn Thorsteinsson, Frederick D. Sancilio, Jason D. Legassie
  • Patent number: 9895407
    Abstract: The present invention provides a disinfecting formulation useful, for example, for cleaning and disinfecting human or animal body parts, and in particular for disinfecting human hands. The disinfecting formulation comprises alcohol including ethanol; an essential oil comprising cineole, in particular eucalyptus oil; an emollient including glycerin; and other ingredients comprising piroctone olamine, acrylic acid based polymer and 2-amino-2-methyl-1-propanol. The invention also provides methods of disinfection of human and animal body parts and methods for preparing the formulation.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: February 20, 2018
    Assignee: Sunny Wipes Pty Ltd
    Inventor: Peter Lawrence Steve
  • Patent number: 9750691
    Abstract: A composition comprising an INTEROMONE® is described for the modification of undesirable or harmful stress-related behaviors or other behaviors or physiology in a variety of vertebrate species, as well as methods of using the compositions in vertebrates from a species different than the species in which the INTEROMONE® is a naturally occurring pheromone.
    Type: Grant
    Filed: September 20, 2012
    Date of Patent: September 5, 2017
    Assignee: Sergeant's Pet Care Products, Inc.
    Inventors: John McGlone, Larry Nouvel
  • Patent number: 9737609
    Abstract: The present disclosure refers to a synergistic blend of Konjac powder and Xanthan gum that is included, as a natural suspending agent, in oral pharmaceutical suspensions. Oral pharmaceutical suspensions comprising the synergistic blend are aqueous solutions. The synergistic blend, used as a suspension agent to suspend suitable active pharmaceutical ingredients (APIs), improves the stability of oral pharmaceutical suspensions, and helps in the formation of a thermo-reversible gel and shear thinning necessary to keep APIs suspended within oral pharmaceutical suspensions. The synergistic blend of Konjac powder and Xanthan gum has unique anti-flocculation properties, which improve the homogeneity of the oral pharmaceutical suspensions. Additionally, the blend provides a better texture and mouth feel.
    Type: Grant
    Filed: August 19, 2015
    Date of Patent: August 22, 2017
    Assignee: Professional Compounding Centers of America (PCCA)
    Inventors: Christine Vu, Fabiana Banov, Daniel Banov
  • Patent number: 9561239
    Abstract: A composition for use in inhibiting the binding of a Norovirus to the histo-blood group antigen on the surface of epithelia is disclosed. The composition may contain a therapeutically effective amount of a binding-inhibiting compound and a carrier and/or excipient. The compounds may competitively bind a Norovirus that has the capability of binding with the histo-blood group antigens of secretor blood type, including A, B, AB, and O blood types. The compositions may be administered to a human prior to or after infection by a Norovirus, to prevent, ameliorate, or reduce the effects of an infection.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: February 7, 2017
    Assignee: Children's Hospital Medical Center
    Inventors: Xi Jiang, Ming Tan, Xufu Zhang
  • Patent number: 9504697
    Abstract: Described herein are therapeutic methods using progesterone and progesterone analogs to improve sleep quality. The methods may be particularly useful to treat subject with perturbed sleep patterns, such as subjects who suffer from mid-sleep period awakenings.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: November 29, 2016
    Assignee: BESINS HEALTHCARE LUXEMBOURG SARL
    Inventors: Anne Caufriez, Georges Copinschi
  • Patent number: 9498436
    Abstract: Solutions of testosterone for oromucosal administration providing an increase in serum testosterone levels in subjects deficient in endogenous testosterone levels, and therapeutic methods for providing an increase in serum testosterone levels and methods for treating a disease or a symptom associated with deficient endogenous levels of testosterone.
    Type: Grant
    Filed: August 9, 2011
    Date of Patent: November 22, 2016
    Assignee: INNOTESTO BVBA
    Inventor: Franciscus Wilhelmus Henricus Maria Merkus
  • Patent number: 9480689
    Abstract: The present disclosure provides for compositions and methods of stimulating reproductive behavior and reproductive success and productivity in a suid, such as pigs. The composition may comprise at least one steroid hormone and a heterocyclic aromatic compound. The method comprises administering the pheromone composition to the suid for a period of time.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: November 1, 2016
    Assignee: Animal Biotech, LLC
    Inventor: John J. McGlone
  • Patent number: 9468647
    Abstract: Endometriosis, including endometriosis externa, endometrioma, adenomyosis, adenomyomas, adenomyotic nodules of the uterosacral ligaments, and endometriotic nodules, such as scar endometriosis are effectively treated by the intralesional administration, including transvaginal, endoscopic or open surgical administration including via laparotomy, of a progestogen. Compositions therefor also are provided.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: October 18, 2016
    Assignee: MISCON TRADING S.A.
    Inventor: Mirudhubashini Govindarajan
  • Patent number: 9408856
    Abstract: The present invention relates to formulations of poorly water soluble pharmaceutical agents of Formula I and II. The present invention also relates to compositions containing compounds of Formula I or II, and glucocorticoids, and methods for reducing side effects from glucocorticoid treatment by co-administration of compounds of Formula I and II. The compositions herein are useful for the treatment of diabetes and obesity related diseases including metabolic syndrome.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: August 9, 2016
    Assignee: TEMPLE UNIVERSITY—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Arthur G Schwartz, John R Williams
  • Patent number: 9402853
    Abstract: The present invention relates to formulations of poorly water soluble pharmaceutical agents of Formula I and II. The present invention also relates to compositions containing compounds of Formula I or II, and glucocorticoids, and methods for reducing side effects from glucocorticoid treatment by co-administration of compounds of Formula I and II. The compositions herein are useful for the treatment of diabetes and obesity related diseases including metabolic syndrome.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: August 2, 2016
    Assignee: TEMPLE UNIVERSITY-OF THE COMMONWEALTH OF HIGHER EDUCATION
    Inventors: Arthur G Schwartz, John R Williams
  • Patent number: 9375476
    Abstract: A pharmaceutical composition of botulinum toxin and an adjuvant is disclosed. The composition is formulated for topical administration to deliver a therapeutically effective dose of botulinum toxin to an area of a subject suffering from inflammation. The botulinum toxin composition reduces a symptom of inflammation without producing substantial muscle weakness. The composition may optionally contain additional anti-inflammatory agents, such as steroidal or non-steroidal agents.
    Type: Grant
    Filed: December 31, 2008
    Date of Patent: June 28, 2016
    Assignee: Botulinum Toxin Research Associates, Inc.
    Inventor: Gary E. Borodic
  • Patent number: 9365609
    Abstract: The present invention provides a process for preparing a crystalline form of halobetasol propionate, comprising the step of crystallizing halobetasol propionate from absolute ethanol or a mixture of ethanol and water, wherein the crystalline form of halobetasol propionate is characterized by an x-ray powder diffraction pattern having peaks at 10.0, 11.6, 12.9, 13.4, 14.5, 16.4, 17.6, and 23.5±0.2 degrees 2?.
    Type: Grant
    Filed: January 7, 2013
    Date of Patent: June 14, 2016
    Assignee: TARO PHARMACEUTICALS NORTH AMERICA, INC.
    Inventors: Daniella Gutman, Shimon Chernyak
  • Patent number: 9339508
    Abstract: A method for the treatment of a traumatic brain lesion comprises administering to the patient an effective quantity of 3?-methoxy-pregna-5-ene-20-one (3?-methoxy-PREG).
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: May 17, 2016
    Assignee: MAPREG
    Inventors: Etienne-Emile Baulieu, Esther Fellous, Paul Robel
  • Patent number: 9322067
    Abstract: Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for a disease, such as treatments that were not initially identified as a treatment for the disease or not expected to be a treatment for a particular disease.
    Type: Grant
    Filed: April 9, 2014
    Date of Patent: April 26, 2016
    Assignee: Caris MPI, Inc.
    Inventors: Daniel D. Von Hoff, David M. Loesch, Arlet Alarcon, Robert J. Penny, Alan Wright, Matthew J. McGinniss, Ryan P. Bender, Traci Pawlowski
  • Patent number: 9320745
    Abstract: The present invention relates to the use of cholest-4-en-3-one derivatives for obtaining a cytoprotective drug, with the exception of a neuroprotective drug.
    Type: Grant
    Filed: March 28, 2007
    Date of Patent: April 26, 2016
    Assignee: TROPHOS
    Inventors: Rebecca Pruss, Bruno Buisson, Thierry Bordet
  • Patent number: 9305137
    Abstract: In one embodiment, the invention provides methods of identifying genes and genetic variants that, either alone or in combination, are important to the pathogenesis of a disease. In another embodiment, the disease is stratified by use of an immune response to disease-associated antigens. In another embodiment, the invention provides methods of identifying pathways that, either alone or in combination, are important to the pathogenesis of a disease. In another embodiment, the invention provides a method of diagnosing or predicting susceptibility to a disease in an individual by determining the presence or absence of genes and genetic variants that, either alone or in combination, are important to the pathogenesis of the disease.
    Type: Grant
    Filed: May 16, 2008
    Date of Patent: April 5, 2016
    Assignee: Cedars-Sinai Medical Center
    Inventors: Stephan R. Targan, Jerome I. Rotter, Kent D. Taylor
  • Patent number: 9278132
    Abstract: A stable ophthalmic pharmaceutical composition for relief, treatment, control, alleviation, or prevention of a pathological ocular condition of the eye comprises: (a) a first polymer, a viscosity of which changes with a change in a concentration of an electrolyte, such as a salt, when added to said first polymer; (b) a second polymer that is different from the first polymer and can modify the viscosity of the first polymer; and (c) an oil. In some embodiments, the composition further comprises a non-ionic surfactant. The composition can form a stable oil-in-water emulsion on storage, but separate into an oil phase and a water phase when applied in the eye. The emulsion can comprises an ophthalmic active pharmaceutical ingredient dissolved in the oil or water phase. The emulsion can provide enhanced stability to said active pharmaceutical ingredient.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: March 8, 2016
    Assignee: Bausch & Lomb Incorporated
    Inventors: Stephen R. Davio, Paramita Sarkar, Zora T. Marlowe, Brian J. Glass, Tammy J. Kleiber
  • Patent number: 9238072
    Abstract: This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained serum levels in plasma but also leads to a more favorable serum level profile. The special lipophilic or partly lipophilic system also allows for the modulation of brain functioning. The invention also relates to the nasal administration of steroid hormones for treatment of female sexual dysfunction (FSD) or female arousal disorder.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: January 19, 2016
    Assignee: MATTERN PHARMA AG
    Inventor: Claudia Mattern
  • Patent number: 9220699
    Abstract: The present document describes a composition for sustained, targeted or sustained and targeted delivery of an active ingredient which includes a complex formed between a carboxyl substituted polymer and a lipid. The present document also describes dosage forms containing the composition, and an active ingredient, and methods of using the same for the treatment of diseases.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: December 29, 2015
    Assignee: KARICI DIAGNOSTICS INC.
    Inventors: Le Tien Canh, Mihaela Friciu, Pompilia Ispas-Szabo, Mircea Alexandru Mateescu
  • Patent number: 9084797
    Abstract: Described herein are therapeutic methods using progesterone and progesterone analogs to improve sleep quality. The methods may be particularly useful to treat subject with perturbed sleep patterns, such as subjects who suffer from mid-sleep period awakenings.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: July 21, 2015
    Assignee: BESINS HEALTHCARE LUXEMBOURG SARL
    Inventors: Anne Caufriez, Georges Copinschi
  • Publication number: 20150148323
    Abstract: Various pharmaceutical formulations are disclosed herein. For example, a pharmaceutical formulation is disclosed comprising ultra-micronized progesterone.
    Type: Application
    Filed: June 18, 2013
    Publication date: May 28, 2015
    Inventors: Janice Louise Cacace, Peter H.R. Periscaner
  • Publication number: 20150140127
    Abstract: Provided is a method for detecting injury to the brain comprising: a) determining the level of a tight junction (TJ) protein in exosomes isolated from a test sample from a subject, wherein the TJ protein is occludin, claudin-3, claudin-5, claudin-12, ZO-1, ZO-2, ZO-3, JAM-A, JAM-B or JAM-C, or any combination thereof; b) comparing the level of the TJ protein in the test sample to the level of the TJ protein in a control sample, wherein an elevated level of the TJ protein in the test sample relative to the level of the TJ protein in the control sample indicates that the subject has an injury to the brain.
    Type: Application
    Filed: June 25, 2013
    Publication date: May 21, 2015
    Applicant: TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Servio H. Ramirez, Slava Rom, Yuri Persidsky
  • Publication number: 20150141350
    Abstract: A nanodevice composition including N-acetyl cysteine linked to a dendrimer, such as a PAMAM dendrimer or a multiarm PEG polymer, is provided. Also provided is a nanodevice for targeted delivery of a compound to a location in need of treatment. The nanodevice includes a PAMAM dendrimer or multiarm PEG polymer, linked to the compound via a disulfide bond. There is provided a nanodevice composition for localizing and delivering therapeutically active agents, the nanodevice includes a PAMAM dendrimer or multiarm PEG polymer and at least one therapeutically active agent attached to the PAMAM dendrimer or multiarm PEG polymer.
    Type: Application
    Filed: September 4, 2014
    Publication date: May 21, 2015
    Inventors: Rangaramanujam M. Kannan, Sujatha Kannan, Roberto Romero, Raghavendra S. Navath, Hui Dai, Anupa R. Menjoge
  • Publication number: 20150133382
    Abstract: The present invention relates to novel genetic markers associated with endometriosis and risk of developing endometriosis, and methods and materials for determining whether a human subject has endometriosis or is at risk of developing endometriosis and the use of such risk information in selectively administering a treatment that at least partially prevents or compensates for an endometriosis related symptom.
    Type: Application
    Filed: January 12, 2015
    Publication date: May 14, 2015
    Applicant: JUNEAU BIOSCIENCES, LLC
    Inventors: Kenneth Ward, Rakesh N. Chettier, Hans Albertsen
  • Patent number: 9029355
    Abstract: In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: May 12, 2015
    Assignee: Marinus Pharmaceuticals
    Inventors: Kenneth Shaw, Mingbao Zhang
  • Publication number: 20150112116
    Abstract: Provided herein are methods comprising providing a tyrosine derivative and a solid particulate material (and, optionally, melanin) and applying force to said tyrosine derivative and said solid particulate material for a time and under conditions effective to impregnate at least one of said tyrosine derivative and said solid particulate material with the other of said tyrosine derivative and said solid particulate material. The invention also provides compositions comprising at least one of a tyrosine derivative impregnated with a solid particulate material and a solid particulate material impregnated with a tyrosine derivative.
    Type: Application
    Filed: October 24, 2013
    Publication date: April 23, 2015
    Inventor: STEVEN HOFFMAN
  • Publication number: 20150111834
    Abstract: The disclosure provides a recipe for in-situ gel, formed by dissolving at least one polymer and at least one gel prevention agent in a polar solvent to form a solution and placing the solution in a condition for in-situ forming gels. The disclosure also provides an implant and a drug delivery system formed by the recipe.
    Type: Application
    Filed: September 17, 2014
    Publication date: April 23, 2015
    Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Felice CHENG, Maggie J.M. LU, Yi-Ju KO, Min-Ying LIN, Shuen-Hsiang CHOU
  • Patent number: 9011908
    Abstract: Fill materials for hydrophobic drugs, such as progesterone, and methods of making and using thereof are described herein. The fill material contains the hydrophobic drug dissolved in one or more fatty acids. The concentration of the hydrophobic drug is typically from about 7% to about 50% by weight of the fill material. The concentration of the one or more fatty acids is from about 60% to about 95% by weight of the carrier. The formulation also contains an organic acid and one or both of one or more pharmaceutically acceptable alcohols and one or more pharmaceutically acceptable mono-, di-, or triesters of medium or long chain fatty acids. The fill material can be encapsulated in a hard or soft capsule. The formulations described herein have a higher dissolution rate and faster onset of dissolution compared to micronized progesterone suspended in an oil and thus should have increased bioavailability in vivo.
    Type: Grant
    Filed: April 1, 2010
    Date of Patent: April 21, 2015
    Assignee: Banner Life Sciences LLC
    Inventors: Zhi Liu, Saujanya L. Gosangari, Dana S. Toops, Aqeel Fatmi
  • Publication number: 20150098978
    Abstract: A tablet that includes a solid solution of soluble fiber and one or more sugar alcohols, the solid solution having a glass transition temperature of less than 40° C., and one or more additives dispersed in the solid solution such that at least one additive is released from the tablet when the tablet is chewed or dissolved within an oral cavity.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 9, 2015
    Inventors: Feng Gao, Diane L. Gee, Phillip M. Hulan, Shuzhong Zhuang, William J. Burke, Gerd Kobal
  • Publication number: 20150094291
    Abstract: The invention provides a method for improving the emotional development of an infant by performing controlled exposure of the infant aged less than six months old to human fear pheromone, preferably with visual fear stimuli, so that the natural synaptic connections in the brain associated with normal fear mechanisms are stimulated and exercised. This can reduce the occurrence of mental illness later in life, in particular reduce the occurrence of schizophrenia. Advantageously the exposure to fear pheromone and visual fear stimuli is terminated and followed by comforting stimuli such as feeding, physical contact, or comforting or happy visual or audible stimuli such as laughter.
    Type: Application
    Filed: October 2, 2013
    Publication date: April 2, 2015
    Applicant: Opendot Research Co Limited
    Inventor: Derek John GOLDSMITH